ArticleVirchows Archiv : an international journal of pathology2026
Diagnostic utility of targeted next-generation sequencing in indeterminate pancreaticobiliary cytology and small biopsy specimens: a prospective cohort study.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreaticobiliary cytology is a highly specific but variably and often insufficiently sensitive diagnostic method. This study evaluated the utility of next-generation sequencing (NGS) in difficult-to-classify pancreaticobiliary specimens. A total of 136 patients were prospectively included, with cytology or small biopsy specimens from the pancreas (n = 74), extrahepatic biliary tree (n = 56), pancreatic duct (n = 4), gallbladder (n = 1), and peripancreatic lymph node (n = 1). All cases were diagnosed by cytopathologists with expertise in pancreaticobiliary (cyto)pathology using 2022 WHO Reporting System for Pancreaticobiliary Cytopathology. Large scale pan-cancer panel was used for NGS testing. Forty-five cases (33,1%) were non-analyzable by NGS, and no genetic changes were found in 21 cases (23,1% of analyzable cases). Separate acquisition and storage of cytology/biopsy materials in RNAlater solution significantly decreased the rate of non-analyzable samples (23.3% versus 44.4%; Fisher's exact test: p = 0.0108, OR = 0.379, 95% CI 0.182-0.792). Diagnostic genetic alterations were identified in 70/91 of analyzable cases (76.9%). Suspicion was raised for the presence of germline mutation in 10 patients. Potentially druggable alterations (n = 42) were found in 36/91 patients (39,5%), including mutations in homologous recombination genes, PI3K/AKT/mTOR pathway, Cyclin D1-CDK4/6-Rb pathway, and potentially targetable KRAS mutations (KRAS G12D mutation occurred in 19/41 [46,3%] of KRAS-mutated tumors). Supplementing pancreaticobiliary (cyto)pathology with information from NGS increased the sensitivity for tumor diagnosis from 35.9% to 86.6% (with specificity 100%), improved negative predictive value from 14.2% to 41.2%, and enhanced overall diagnostic accuracy from 42.1% to 87.8%, respectively. In challenging cases, NGS significantly improves preoperative pancreaticobiliary diagnosis and informs clinical decision-making.
Indexed as
Identifiers
42056264What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.